Rapamycin selectively inhibits expression of an inducib keratinocytes and improves symptoms in pachyonychia

Journal of Dermatological Science

56, 82-88

DOI: 10.1016/j.jdermsci.2009.07.008

Citation Report

#	Article	IF	CITATIONS
1	elF4E, the mRNA cap-binding protein: from basic discovery to translational researchThis paper is one of a selection of papers published in this Special Issue, entitled CSBMCB — Systems and Chemical Biology, and has undergone the Journal's usual peer review process Biochemistry and Cell Biology, 2008, 86, 178-183.	2.0	178
2	Toll-Like Receptors: Role in Dermatological Disease. Mediators of Inflammation, 2010, 2010, 1-16.	3.0	85
3	Keratin gene mutations in disorders of human skin and its appendages. Archives of Biochemistry and Biophysics, 2011, 508, 123-137.	3.0	160
4	Surgery of the nail bed. , 2011, , 55-84.		0
5	What′s new in nail disorders?. Indian Journal of Dermatology, Venereology and Leprology, 2011, 77, 631.	0.6	3
6	Onychopathy Induced by Temsirolimus, a Mammalian Target of Rapamycin Inhibitor. Dermatology, 2012, 224, 204-208.	2.1	26
7	Progress towards genetic and pharmacological therapies for keratin genodermatoses: current perspective and future promise. Experimental Dermatology, 2012, 21, 481-489.	2.9	34
8	Visible effects of rapamycin (sirolimus) on human skin explants in vitro. Archives of Dermatological Research, 2013, 305, 163-171.	1.9	9
9	Management of ichthyosis and related conditions gene-based diagnosis and emerging gene-based therapy. Dermatologic Therapy, 2013, 26, 55-68.	1.7	6
11	Pachyonychia congenita cornered: report on the 11th <scp>A</scp> nnual <scp>I</scp> nternational <scp>P</scp> achyonychia <scp>C</scp> ongenita <scp>CMeeting. British Journal of Dermatology, 2014, 171, 974-977.</scp>)> dr æortiu	m10
12	Best treatment practices for pachyonychia congenita. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 279-285.	2.4	44
13	Severe Skin Diseases in Children. , 2014, , .		0
14	mTOR signaling and its involvement in the regulation of cell movements through remodeling the cytoskeleton architecture. Biopolymers and Cell, 2015, 31, 5-14.	0.4	3
15	Gene expression profiling in pachyonychia congenita skin. Journal of Dermatological Science, 2015, 77, 156-165.	1.9	33
16	Advances in the therapeutic use of mammalian target of rapamycin (mTOR) inhibitors in dermatology. Journal of the American Academy of Dermatology, 2015, 72, 879-889.	1.2	46
17	The twisting tale of woolly hair: a trait with many causes. Journal of Medical Genetics, 2015, 52, 217-223.	3.2	17
18	Elucidation of the mTOR Pathway and Therapeutic Applications in Dermatology. Actas Dermo-sifiliogrÃ _i ficas, 2016, 107, 379-390.	0.4	4
19	Utilidad de la rapamicina tópica en dermatologÃa pediátrica. Piel, 2016, 31, 715-720.	0.0	0

CITATION REPORT

#	Article	IF	CITATIONS
20	Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatologic Therapy, 2016, 29, 32-36.	1.7	19
21	Peripheral neuropathic changes in pachyonychia congenita. Pain, 2016, 157, 2843-2853.	4.2	20
22	Bases moleculares y aplicaciones farmacológicas de la vÃa de mTOR en dermatologÃa. Actas Dermo-sifiliográficas, 2016, 107, 379-390.	0.4	14
23	Successful Treatment of a Complex Vascular Malformation With Sirolimus and Surgical Resection. Journal of Pediatric Hematology/Oncology, 2017, 39, e191-e195.	0.6	11
24	Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice. Acta Dermato-Venereologica, 2017, 97, 1087-1094.	1.3	49
25	Management of Plantar Keratodermas. Journal of the American Podiatric Medical Association, 2017, 107, 428-435.	0.3	3
26	Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation. PLoS ONE, 2017, 12, e0180853.	2.5	54
27	Neuroendocrine Controls of Keratin Expression in Human Skin. , 2018, , .		0
28	The physical and chemical disruption of human hair after bleaching – studies by transmission electron microscopy and redox proteomics. International Journal of Cosmetic Science, 2018, 40, 536-548.	2.6	21
29	Plantar pain in pachyonychia congenita. British Journal of Dermatology, 2018, 179, 11-12.	1.5	7
30	Dermoscopy and confocal microscopy: come together, right now?. British Journal of Dermatology, 2018, 179, 12-13.	1.5	0
31	Novel treatment of painful plantar keratoderma in pachyonychia congenita using topical sirolimus. Clinical and Experimental Dermatology, 2018, 43, 968-971.	1.3	16
32	Pachyonychia congenita responding favorably to a combination of surgical and medical therapies. Dermatologic Therapy, 2019, 32, e13045.	1.7	5
35	Pathophysiology of pachyonychia congenitaâ€associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment. British Journal of Dermatology, 2020, 182, 564-573.	1.5	38
36	Keratin 6a mutations lead to impaired mitochondrial quality control. British Journal of Dermatology, 2020, 182, 636-647.	1.5	17
37	Pain mechanisms in hereditary palmoplantar keratodermas. British Journal of Dermatology, 2020, 182, 543-551.	1.5	8
38	Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome. JAMA Dermatology, 2020, 156, 196.	4.1	21
39	Successful treatment of Pachyonychia congenita with Rosuvastatin. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e480-e482.	2.4	7

#	Article	IF	CITATIONS
40	Pachyonychia congenita, a paradigm for rare skin disorders. British Journal of Dermatology, 2020, 182, 521-522.	1.5	3
41	Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature*. British Journal of Dermatology, 2021, 184, 393-400.	1.5	17
42	Genotype‒Structurotype‒Phenotype Correlations in Patients with Pachyonychia Congenita. Journal of Investigative Dermatology, 2021, 141, 2876-2884.e4.	0.7	10
43	Transcriptomic Repositioning Analysis Identifies mTOR Inhibitor as Potential Therapy for Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2022, 142, 382-389.	0.7	7
44	Disorders of Hair and Nails. , 2016, , 136-174.e9.		2
45	Diagnosis and Management of Inherited Palmoplantar Keratodermas. Acta Dermato-Venereologica, 2020, 100, adv00094-176.	1.3	13
46	Disorders of Hair and Nails. , 2011, , 130-166.		2
47	Current and Novel Approaches for Genetic Skin Disorders. , 2014, , 189-202.		0
48	A Rare Genetic Disease: Pachyonychia Congenita Type 2. Turkish Journal of Pediatric Disease, 2013, 7, 193-195.	0.0	0
49	Queratodermia plantar dolorosa y onicodistrofia en mujer joven caucásica. Dermatology Online Journal, 2015, 21, .	0.5	0
50	Drug Repurposing Reveals mTOR Inhibition as a Promising Strategy for Epidermolysis Bullosa Simplex. Journal of Investigative Dermatology, 2022, 142, 275-278.	0.7	0
51	Genotype-phenotype correlations of neurovascular structures on the feet in patients with pachyonychia congenita: A cross-sectional study. Journal of the American Academy of Dermatology, 2022, 87, 1172-1174.	1.2	3
52	Treatment of Painful Palmoplantar Keratoderma Related to Pachyonychia Congenita Using EGFR Inhibitors. Biomedicines, 2022, 10, 841.	3.2	6
53	EGFR Signaling Is Overactive in Pachyonychia Congenita: Effective Treatment with Oral Erlotinib. Journal of Investigative Dermatology, 2023, 143, 294-304.e8.	0.7	10
54	mTORC1 Activity in Psoriatic Lesions Is Mediated by Aberrant Regulation through the Tuberous Sclerosis Complex. Cells, 2022, 11, 2847.	4.1	3
56	Pachyonychia Congenita: Clinical Features and Future Treatments. Keio Journal of Medicine, 2023, , .	1.1	0
57	Posttranslational modifications of keratins and their associated proteins as therapeutic targets in keratin diseases. Current Opinion in Cell Biology, 2023, 85, 102264.	5.4	0
58	Pachyonychia Congenita: A Research Agenda Leading to New Therapeutic Approaches. Journal of Investigative Dermatology, 2023, , .	0.7	0

CITATION REPORT

#	Article	IF	CITATIONS
60	A novel heterozygous frameshift mutation in the KRT6A gene responsible for an uncommon phenotype of pachyonychia congenita: One case report and review of literature. Heliyon, 2024, 10, e27195.	3.2	0